Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1940 1
1954 1
1965 1
1979 1
1984 1
1993 2
1995 2
1997 1
1998 1
1999 1
2000 1
2001 1
2004 1
2009 3
2010 3
2011 3
2012 8
2013 10
2014 8
2015 5
2016 7
2017 4
2018 5
2019 3
2020 2
2021 8
2022 7
2023 10
2024 12
2025 13

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

110 results

Results by year

Filters applied: . Clear all
Page 1
Liquid biopsy-based protein biomarkers for risk prediction, early diagnosis, and prognostication of cholangiocarcinoma.
Lapitz A, Azkargorta M, Milkiewicz P, Olaizola P, Zhuravleva E, Grimsrud MM, Schramm C, Arbelaiz A, O'Rourke CJ, La Casta A, Milkiewicz M, Pastor T, Vesterhus M, Jimenez-Agüero R, Dill MT, Lamarca A, Valle JW, Macias RIR, Izquierdo-Sanchez L, Pérez Castaño Y, Caballero-Camino FJ, Riaño I, Krawczyk M, Ibarra C, Bustamante J, Nova-Camacho LM, Falcon-Perez JM, Elortza F, Perugorria MJ, Andersen JB, Bujanda L, Karlsen TH, Folseraas T, Rodrigues PM, Banales JM. Lapitz A, et al. Among authors: dill mt. J Hepatol. 2023 Jul;79(1):93-108. doi: 10.1016/j.jhep.2023.02.027. Epub 2023 Mar 1. J Hepatol. 2023. PMID: 36868481 Free PMC article.
NIBR-LTSi is a selective LATS kinase inhibitor activating YAP signaling and expanding tissue stem cells in vitro and in vivo.
Namoto K, Baader C, Orsini V, Landshammer A, Breuer E, Dinh KT, Ungricht R, Pikiolek M, Laurent S, Lu B, Aebi A, Schönberger K, Vangrevelinghe E, Evrova O, Sun T, Annunziato S, Lachal J, Redmond E, Wang L, Wetzel K, Capodieci P, Turner J, Schutzius G, Unterreiner V, Trunzer M, Buschmann N, Behnke D, Machauer R, Scheufler C, Parker CN, Ferro M, Grevot A, Beyerbach A, Lu WY, Forbes SJ, Wagner J, Bouwmeester T, Liu J, Sohal B, Sahambi S, Greenbaum LE, Lohmann F, Hoppe P, Cong F, Sailer AW, Ruffner H, Glatthar R, Humar B, Clavien PA, Dill MT, George E, Maibaum J, Liberali P, Tchorz JS. Namoto K, et al. Among authors: dill mt. Cell Stem Cell. 2024 Apr 4;31(4):554-569.e17. doi: 10.1016/j.stem.2024.03.003. Cell Stem Cell. 2024. PMID: 38579685 Free article.
Lymphotoxin beta-activated LTBR/NIK/RELB axis drives proliferation in cholangiocarcinoma.
Xu K, Kessler A, Nichetti F, Hoffmeister-Wittmann P, Scherr AL, Nader L, Kelmendi E, Schmitt N, Schwab M, García-Beccaria M, Sobol B, Nieto OA, Isele H, Gärtner U, Vaquero-Siguero N, Volk J, Korell F, Mock A, Heide D, Ramadori P, Lenoir B, Albrecht T, Hüllein J, Jäger D, Fröhling S, Springfeld C, Jackstadt R, Heikenwälder M, Dill MT, Roessler S, Goeppert B, Köhler BC. Xu K, et al. Among authors: dill mt. Liver Int. 2024 Nov;44(11):2950-2963. doi: 10.1111/liv.16069. Epub 2024 Aug 20. Liver Int. 2024. PMID: 39164890 Free article.
Comprehensive Molecular Characterization of the Hippo Signaling Pathway in Cancer.
Wang Y, Xu X, Maglic D, Dill MT, Mojumdar K, Ng PK, Jeong KJ, Tsang YH, Moreno D, Bhavana VH, Peng X, Ge Z, Chen H, Li J, Chen Z, Zhang H, Han L, Du D, Creighton CJ, Mills GB; Cancer Genome Atlas Research Network; Camargo F, Liang H. Wang Y, et al. Among authors: dill mt. Cell Rep. 2018 Oct 30;25(5):1304-1317.e5. doi: 10.1016/j.celrep.2018.10.001. Cell Rep. 2018. PMID: 30380420 Free PMC article.
Burnout Among Physicians With Disabilities.
Meeks LM, Conrad SS, Nouri Z, Moreland CJ, Sheets ZC, Hu X, Dill MJ. Meeks LM, et al. Among authors: dill mj. JAMA Netw Open. 2024 May 1;7(5):e2410701. doi: 10.1001/jamanetworkopen.2024.10701. JAMA Netw Open. 2024. PMID: 38722631 Free PMC article.
Safety and efficacy of elafibranor in primary sclerosing cholangitis: The ELMWOOD phase II randomized-controlled trial.
Levy C, Abouda GF, Bilir BM, Bonder A, Bowlus CL, Campos-Varela I, Cazzagon N, Chandok N, Cheent K, Cortez-Pinto H, Demir M, Dill MT, Eksteen B, Fenkel JM, Gilroy R, Ko HH, Jacobson IM, Kallis Y, Kugelmas M, Luketic V, Mangia A, Montano-Loza AJ, Mukhopadhya A, Olveira A, Patel BC, Pietrangelo A, Pradhan F, Salcedo M, Shiffman ML, Sprinzl K, Swann R, Thorburn D, Thuluvath PJ, Trivedi PJ, Turnes J, Zein CO, Gomes da Silva H, Jaitly S, Miller B, Milligan C, Tavenard A, Kowdley KV. Levy C, et al. Among authors: dill mt. J Hepatol. 2025 May 8:S0168-8278(25)00252-1. doi: 10.1016/j.jhep.2025.04.025. Online ahead of print. J Hepatol. 2025. PMID: 40350321 Free article.
Efficacy, safety and differential outcomes of immune-chemotherapy with gemcitabine, cisplatin and durvalumab in patients with biliary tract cancers: A multicenter real world cohort.
Mitzlaff K, Kirstein MM, Müller C, Venerito M, Olkus A, Dill MT, Weinmann A, Kocheise L, Busch A, Schulze K, Allo G, Waldschmidt DT, Barsch M, Bengsch B, Quante M, Gonzalez-Carmona MA, Himmelsbach V, Finkelmeier F, Kloeckner R, Schirmacher P, Marquardt JU, Zimpel C. Mitzlaff K, et al. Among authors: dill mt. United European Gastroenterol J. 2024 Nov;12(9):1230-1242. doi: 10.1002/ueg2.12656. Epub 2024 Sep 20. United European Gastroenterol J. 2024. PMID: 39301763 Free PMC article.
110 results